zoldonrasib
zoldonrasib: developed by 1 company · 7 clinical trials tracked.
zoldonrasib evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
How could zoldonrasib → RVMD affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| REVOLUTION MEDICINES, INC. (RVMD) Advanced Solid Tumors; NSCLC; Pancreatic Cancer | Phase 3 |
Clinical Trials (7)
A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)
Primary endpoint: Progression free survival (PFS)
RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
Primary endpoint: Progression free survival (PFS)
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors
Primary endpoint: Number of patients with adverse events (AEs)
A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation
Primary endpoint: Phase 1: Maximum Tolerated Dose
A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Primary endpoint: Adverse events
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
Primary endpoint: Adverse events
Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors
Primary endpoint: Adverse events
Frequently asked questions
Who is developing zoldonrasib?
zoldonrasib is being developed by REVOLUTION MEDICINES, INC..
How many clinical trials involve zoldonrasib?
BioSniper tracks 7 clinical trials involving zoldonrasib.